Skip to main content

Advertisement

Table 1 Baseline patient and disease characteristics

From: Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma

Characteristics Patients
Number Percentage
Gender Male 6 43 %
Female 8 57 %
Age, years; median (range) 62 (48–76)
WHO performance status 0 10 71 %
1 4 29 %
Time from diagnosis of metastatic pancreas cancer to trial entry, adays; median (range) 13 (5–434)
Cancer stage at diagnosis TX 4 29 %
T2 6 43 %
T3 2 14 %
T4 2 14 %
Primary tumour in situ Yes 10 71 %
No 4 29 %
Metastases Liver only 8 57 %
Liver and lung 2 14.5 %
Liver and lymph nodes 2 14.5 %
Liver, lung and lymph nodes 1 7 %
Liver, lung, lymph nodes, soft tissue 1 7 %
Number of metastatic sites; median (range) 3 (1–5)
CA19-9, bU/mL; median (range) 3480 (33–280,000)
>ULN 13 93 %
Prior lines of chemotherapy for metastatic disease 0 13 93 %
1 1 7 %
  1. aTrial entry defined as day of informed consent
  2. bN = 13 patients with elevated CA19-9 baseline levels (ULN 37 U/mL)